These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24284914)

  • 1. Antibodies to watch in 2014.
    Reichert JM
    MAbs; 2014 Jan; 6(1):5-14. PubMed ID: 24284914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to watch in 2015.
    Reichert JM
    MAbs; 2015; 7(1):1-8. PubMed ID: 25484055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to watch in 2016.
    Reichert JM
    MAbs; 2016; 8(2):197-204. PubMed ID: 26651519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to watch in 2017.
    Reichert JM
    MAbs; 2017; 9(2):167-181. PubMed ID: 27960628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to watch in 2014: mid-year update.
    Reichert JM
    MAbs; 2014; 6(4):799-802. PubMed ID: 24846335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to watch in 2020.
    Kaplon H; Muralidharan M; Schneider Z; Reichert JM
    MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which are the antibodies to watch in 2013?
    Reichert JM
    MAbs; 2013; 5(1):1-4. PubMed ID: 23254906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to watch in 2018.
    Kaplon H; Reichert JM
    MAbs; 2018; 10(2):183-203. PubMed ID: 29300693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to watch in 2019.
    Kaplon H; Reichert JM
    MAbs; 2019; 11(2):219-238. PubMed ID: 30516432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to watch in 2021.
    Kaplon H; Reichert JM
    MAbs; 2021; 13(1):1860476. PubMed ID: 33459118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to watch in 2013: Mid-year update.
    Reichert JM
    MAbs; 2013; 5(4):513-7. PubMed ID: 23727858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-based therapeutics to watch in 2011.
    Reichert JM
    MAbs; 2011; 3(1):76-99. PubMed ID: 21051951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to watch in 2022.
    Kaplon H; Chenoweth A; Crescioli S; Reichert JM
    MAbs; 2022; 14(1):2014296. PubMed ID: 35030985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.
    Mazhar F; Haider N
    J Pharmacol Pharmacother; 2016; 7(4):190-193. PubMed ID: 28163543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to watch in 2023.
    Kaplon H; Crescioli S; Chenoweth A; Visweswaraiah J; Reichert JM
    MAbs; 2023; 15(1):2153410. PubMed ID: 36472472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
    Wang EQ; Bukowski JF; Yunis C; Shear CL; Ridker PM; Schwartz PF; Baltrukonis D
    BioDrugs; 2019 Oct; 33(5):571-579. PubMed ID: 31529318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.